Eli Lilly has moved to expand its neuroscience portfolio by agreeing to acquire 4E Therapeutics. Market analysts view the deal as a calculated effort by the drug maker to accelerate the development of next-generation painkillers. Meanwhile, the sector saw a notable regulatory breakthrough as Amphastar Pharmaceuticals secured FDA approval for an over-the-counter nasal spray designed to treat opioid overdoses, marking a significant expansion in access to emergency treatment options.